Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Loberg

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Prostate Cancer|July 5, 2005
The "emigration, migration, and immigration"of prostate cancerKenneth J Pienta, Robert Loberg
Cancer Metastasis Reviews|December 14, 2006
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasisJianhua Wang, Robert Loberg, Russell S Taichman
American Journal of Clinical Pathology|December 6, 2021
Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and DiagnosticsJohn D Pfeifer, Robert Loberg, Catherine Lofton-Day, et al.
Cancer Research|January 30, 2009
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in boneXin Li, Robert Loberg, Jinhui Liao, et al.
Cancer Letters|October 19, 2004
Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell linesSheri Nixdorf, Marc-Oliver Grimm, Robert Loberg, et al.
The Journal of Biological Chemistry|December 7, 2007
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancerJianhua Wang, Yusuke Shiozawa, Jincheng Wang, et al.
Molecular Cancer Therapeutics|August 31, 2013
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer modelsTammy L Bush, Marc Payton, Scott Heller, et al.
Journal of Translational Medicine|November 5, 2014
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissuesGloria Juan, Tammy L Bush, Connie Ma, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Journal of Medicinal Chemistry|November 18, 2011
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitorsLaurie B Schenkel, Xin Huang, Alan Cheng, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Prostate Cancer|July 5, 2005
The "emigration, migration, and immigration"of prostate cancerKenneth J Pienta, Robert Loberg
Cancer Metastasis Reviews|December 14, 2006
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasisJianhua Wang, Robert Loberg, Russell S Taichman
American Journal of Clinical Pathology|December 6, 2021
Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and DiagnosticsJohn D Pfeifer, Robert Loberg, Catherine Lofton-Day, et al.
Cancer Research|January 30, 2009
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in boneXin Li, Robert Loberg, Jinhui Liao, et al.
Cancer Letters|October 19, 2004
Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell linesSheri Nixdorf, Marc-Oliver Grimm, Robert Loberg, et al.
The Journal of Biological Chemistry|December 7, 2007
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancerJianhua Wang, Yusuke Shiozawa, Jincheng Wang, et al.
Molecular Cancer Therapeutics|August 31, 2013
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer modelsTammy L Bush, Marc Payton, Scott Heller, et al.
Journal of Translational Medicine|November 5, 2014
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissuesGloria Juan, Tammy L Bush, Connie Ma, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Journal of Medicinal Chemistry|November 18, 2011
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitorsLaurie B Schenkel, Xin Huang, Alan Cheng, et al.
Pageof 1